Clinical Cancer Research The Science of Cancer Health Disparities
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Määttä, M.
Right arrow Articles by Autio-Harmainen, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Määttä, M.
Right arrow Articles by Autio-Harmainen, H.
Clinical Cancer Research Vol. 6, 2726-2734, July 2000
© 2000 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Differential Expression of Matrix Metalloproteinase (MMP)-2, MMP-9, and Membrane Type 1-MMP in Hepatocellular and Pancreatic Adenocarcinoma: Implications for Tumor Progression and Clinical Prognosis1

Marko Määttä2, Ylermi Soini, Annikki Liakka and Helena Autio-Harmainen

Department of Pathology, University of Oulu, 90014 Oulu, Finland

In the present study, we used in situ hybridization to study 36 primary hepatocellular carcinomas (HCCs) and 35 pancreatic adenocarcinomas to analyze the expressions of membrane-type 1 matrix metalloproteinase (MT1-MMP), MMP-2, and MMP-9 mRNAs. In HCCs, MT1-MMP mRNA was mainly expressed by cancer cells and to a lesser extent by stromal cells. MMP-2 mRNA was expressed predominantly by cells of tumor stroma, whereas MMP-9 mRNA was seen mainly in neoplastic epithelial cells. In pancreatic adenocarcinomas, MT1-MMP and MMP-9 mRNA were seen at moderate levels both in cancer and in stromal cells, whereas MMP-2 mRNA was predominantly expressed by the tumor stroma. Antigens of MMP-2, MMP-9, and MT1-MMP immunolocalized to the neoplastic epithelium and to the stromal cells in both tumor types. In gelatin zymography, increased amounts of latent and active MMP-2 were found in tumor samples of HCC as compared with adjacent nontumorous liver tissue. On the other hand, the latent form of MMP-9 was found in almost equal amounts both in tumor and normal liver samples, but its active form was present only in HCC.

Expression of MT1-MMP mRNA had a tendency to be associated with a lower degree of differentiation in HCC, but such association was not noticed in pancreatic tumors. Correlation to the clinical data showed that MT1-MMP expression had a strong statistical association with a poor outcome of patients (P < 0.01). A similar tendency was also observed in pancreatic adenocarcinomas, but the association did not reach statistical significance. MMP-2 and MMP-9 mRNA expression did not have significant correlation with prognosis. The results of this study support the previous suggestions of the importance of MT1-MMP for malignant growth and indicate that increased MT1-MMP mRNA expression by tumor cells in HCCs and pancreatic adenocarcinomas may have prognostic significance.




This article has been cited by other articles:


Home page
GutHome page
H Yoshiji, S Kuriyama, R Noguchi, J Yoshii, Y Ikenaka, K Yanase, T Namisaki, M Kitade, M Uemura, T Masaki, et al.
Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice
Gut, December 1, 2005; 54(12): 1768 - 1775.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. E. Jones, M. J. Humphreys, F. Campbell, J. P. Neoptolemos, and M. T. Boyd
Comprehensive Analysis of Matrix Metalloproteinase and Tissue Inhibitor Expression in Pancreatic Cancer: Increased Expression of Matrix Metalloproteinase-7 Predicts Poor Survival
Clin. Cancer Res., April 15, 2004; 10(8): 2832 - 2845.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y.-P. Han, L. Zhou, J. Wang, S. Xiong, W. L. Garner, S. W. French, and H. Tsukamoto
Essential Role of Matrix Metalloproteinases in Interleukin-1-induced Myofibroblastic Activation of Hepatic Stellate Cell in Collagen
J. Biol. Chem., February 6, 2004; 279(6): 4820 - 4828.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B.-C. Sheu, H.-C. Lien, H.-N. Ho, H.-H. Lin, S.-N. Chow, S.-C. Huang, and S.-M. Hsu
Increased Expression and Activation of Gelatinolytic Matrix Metalloproteinases Is Associated with the Progression and Recurrence of Human Cervical Cancer
Cancer Res., October 1, 2003; 63(19): 6537 - 6542.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
M. Bloomston, E. E. Zervos, and A. S. Rosemurgy II
Matrix Metalloproteinases and Their Role in Pancreatic Cancer: A Review of Preclinical Studies and Clinical Trials
Ann. Surg. Oncol., August 1, 2002; 9(7): 668 - 674.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
C. A. Iacobuzio-Donahue, B. Ryu, R. H. Hruban, and S. E. Kern
Exploring the Host Desmoplastic Response to Pancreatic Carcinoma : Gene Expression of Stromal and Neoplastic Cells at the Site of Primary Invasion
Am. J. Pathol., January 1, 2002; 160(1): 91 - 99.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.